Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (19849)	3/18/1999 5:24:00 PM
From: DaiS	Read Replies (4) \| Respond to of 23519

Blankmind, This old post gives a summary of the basic gene therapy idea - things have advanced considerably since then... Message 5319236 To all, I am sorry to have misinterpreted some observations about the gene therapy work in what I called the "tissue distribution problem". I drew the conclusion that the gene construct must be fairly evenly distributed throughout the penis to give an "even" erection. Rather the problem is ensuring that the injected gene is expressed (ie produces the channel proteins) not too distant from the site of injection. It appears that this is what one of the AUA abstracts is about this and shows that the expressions IS local - GOOD. I wish Ed or BigK could confirm this. I am out of my mind not being able to read the AUA abstracts. AUA told me they will be on the site later in the month, and Dr Christ is away at present so I cannot check with him. BigK, is the combo study by Nehra sponsored by Vivus? It is not one of the five that you posted as being sponsored by Vivus and you only posted a single non-Vivus study from Korea. What about the combo study? DaiS

To: blankmind who wrote (19849)	3/18/1999 6:19:00 PM
From: VLAD	Respond to of 23519

blankmind, What don't you understand about how gene therapy and how it works in ED? Dr Christ has already proved that calcium channel pumps (which were genetically engineered proteins produced from human genes and proved to be effective in the lab when injected into the penises of rats with vascular ED) can probably be used to "cure" vascular ED in humans via penile injections. So far it appears that a single injection can last up to 75 days. If the product does get to market we are looking at a rather expensive injection that the organic vascular ED patient will need to visit the doctor once every 2 months for administration.

To: blankmind who wrote (19849)	3/18/1999 8:14:00 PM
From: Mkilloran	Respond to of 23519

blankmind...answers to your questions: When is Alibra expected to be approved for sale...about 6 months after it is submitted for NDA..after phase III FDA trials are completed Vivus can submit it's request.est Sept 99 for NDA request .March 2000 should see Alibra onsale ..... Alibra is more effective and a lot cheaper t make than Muse it does not needt to be stored in the frig..store it at room temp...expect yr 2000 profit est to be raised by Alibra introduction.. .stock value to go up in advance of actual sales Female SD product as stated in the press release could be 1-2 years out in the future...by using data already used in testing Muse and Alibra. Gene Therapy ( the non tech description) is like putting fuel injector cleaner in your car .helps it run better need to put it in several times a year to keep your injector clean and working well.. (see Diaz for the real science vrs my laymans analogy)